Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
07/2003
07/01/2003US6586397 Polypeptides encoding tyrosine kinase containing immunoglobulin and endithelial growth factor homology domains; induce vascularization
07/01/2003US6586396 Subcutaneous administration of natriuretic peptide
07/01/2003US6586395 Apoptosis-modulating proteins
07/01/2003US6586394 Tissue-derived tumor growth inhibitor
07/01/2003US6586392 Conjugates of antiviral proteins or peptides and virus or viral envelope glycoproteins
07/01/2003US6586390 Diagnostics, forensics, genetic mapping
07/01/2003US6586389 Cubilin protein, DNA sequences encoding cubilin and uses thereof
07/01/2003US6586388 Method of using recombinant osteogenic protein to repair bone or cartilage defects
07/01/2003US6586244 Compositions and methods for treating neoplastic disease using inhibitors of laminin5beta3
07/01/2003US6586240 Nucleic acid encoding a fusion protein which comprises a fluorescent domain and a binding domain obtained from a protein; use for determining location and movement
07/01/2003US6586228 Nucleic acid which hybridizes to the coding portion of given sequence; DNAX Interferon-like Receptor Subunits (DIRS); use in diagnosis of immune system disorders
07/01/2003US6586227 Non-virulent Porphyromonas gingivalis mutant
07/01/2003US6586226 Efficient purification of adenovirus
07/01/2003US6586222 Recombinant PR-3 and compositions thereof
07/01/2003US6586210 Polynucleotides encoding T1 receptor like ligand II
07/01/2003US6586208 Controlling the generation of poisonous protein; obtain cell, transform with vector coding poisonous protein, express vector, recover protein
07/01/2003US6586206 Methods for making recombinant proteins using apoptosis inhibitors
07/01/2003US6586205 43239 a novel GPCR-like molecule and uses thereof
07/01/2003US6586204 For diagnosing degenerative disorders characterized in inappropriate cell proliferation or inappropriate cell death; formonitoring the progress of such degenerative disorders
07/01/2003US6586203 ARF-P19, a novel regulator of the mammalian cell cycle
07/01/2003US6586192 Compositions and methods for use in affecting hematopoietic stem cell populations in mammals
07/01/2003US6586191 Isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a
07/01/2003US6586189 Screening method for PPAR-γ ligands
07/01/2003US6586182 Selecting amino acid sequence variations based on computer modeling; polynucleotides comprising subsequences of nucleic acids encoding the amino acid variations; reassembling into nucleotide sequences encoding mutagenized polypeptides
07/01/2003US6586179 Human Eag2
07/01/2003US6586174 Detecting CD8+ by contacting with culture of cells that contain recombinant DNA expression vector in which a reporter gene is associated with promoter sequence; measuring inhibition of reporter gene; can use in drugs for AIDS
07/01/2003US6585980 Flagellin gene, FlaC of Campylobacter
07/01/2003US6585979 Immunogenic composition comprising a first polypeptide comprising a gp120 MN sequence and a polypeptide comprising a breakthrough isolate gp120 sequence in a suitable carrier
07/01/2003US6585978 EIA vaccine and diagnostic
07/01/2003US6585977 Non-virulent Porphyromonas gingivalis mutant
07/01/2003US6585976 Selected from Mycobacterium tuberculosis species and Mycobacterium bovis species, and wherein said strain is incapable of expressing the product of the active erp gene
07/01/2003US6585968 Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
07/01/2003CA2177049C Adsorbent for interleukins, process for removing the same, and adsorber for the same
07/01/2003CA2168037C Transformation systems for the yeast candida utilis and the expression of heterologous genes therewith
07/01/2003CA2123303C Icams immunoglobulin constant region soluble fusion proteins
07/01/2003CA2122338C Novel human cdc25 genes, encoded products and uses therefor
07/01/2003CA2086509C Non-cleavable soluble hybrid gp160 variant
07/01/2003CA2069654C Peptide process
07/01/2003CA2067469C Recombinant vaccine against marek's disease
07/01/2003CA2046917C Polypeptides having thyrotropin-receptor activity, nucleic acid sequences coding for such receptors and polypeptides, and applications of these polypeptides
06/2003
06/26/2003WO2003052414A1 Screening method
06/26/2003WO2003052378A2 Compositions, methods and kits relating to thrombin degradation resistant fibroblast growth factor-1
06/26/2003WO2003052377A2 41 human secreted proteins
06/26/2003WO2003052122A2 Gp41 inhibitor
06/26/2003WO2003052119A2 Transporters and ion channels
06/26/2003WO2003052110A2 Nucleic acid nematicides
06/26/2003WO2003052100A1 Use of bard1 inhibitors for promoting cell survival
06/26/2003WO2003052096A1 Mtehod of analyzing gene expression
06/26/2003WO2003052095A2 Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell
06/26/2003WO2003052094A2 Expression vector for the production of annexin v
06/26/2003WO2003052091A1 Growth factor modified protein matrices for tissue engineering
06/26/2003WO2003052086A1 Immune related neuronal receptors and therapeutic uses thereof
06/26/2003WO2003052083A2 Methods for the generation of proliferating and differentiating cell lines
06/26/2003WO2003052082A2 Fusion partner cells and uses thereof
06/26/2003WO2003052079A2 Mutants of human insulin-like growth factor binding protein-3 (igfbp-3) and uses thereof
06/26/2003WO2003052078A2 Insect g protein-coupled receptor genes and uses thereof
06/26/2003WO2003052076A2 Identification of essential genes of cryptococcus neoformans and methods of use
06/26/2003WO2003052075A2 Enzymes
06/26/2003WO2003052073A2 Novel corn event
06/26/2003WO2003052068A2 Mbcats as modifiers of the beta-catenin pathway and methods of use
06/26/2003WO2003052064A2 Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media
06/26/2003WO2003052061A2 Novel human proteins, polynucleotides encoding them and methods of using the same
06/26/2003WO2003052052A2 Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
06/26/2003WO2003052051A2 Adeno-associated virus (aav) serotype 8 sequences
06/26/2003WO2003052049A2 Molecules for disease detection and treatment
06/26/2003WO2003052048A2 Nucleic acid-associated proteins
06/26/2003WO2003051925A1 Human secretin-type gpcr (latrophilin)
06/26/2003WO2003051924A1 Regulation of human integrin alpha-l
06/26/2003WO2003051923A2 Novel g-protein coupled receptors and dna sequences thereof
06/26/2003WO2003051922A1 Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor
06/26/2003WO2003051921A1 Chemokine mutants acting as chemokine antagonists
06/26/2003WO2003051920A1 A method for inducing apoptosis
06/26/2003WO2003051919A1 Secreted mucin-like proteins
06/26/2003WO2003051918A1 Solution-phase process for the manufacture of decapeptide
06/26/2003WO2003051917A2 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
06/26/2003WO2003051915A1 A modulation protein with apoptosis coronary heart disease
06/26/2003WO2003051914A2 Ides, an igg-degrading enzyme of streptococcus pyogenes
06/26/2003WO2003051913A2 Antigens for actinobacillus pleuropneumoniae and methods thereof
06/26/2003WO2003051912A2 Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
06/26/2003WO2003051911A2 Gmg-5 polynucleotides and polypeptides and uses thereof
06/26/2003WO2003051910A2 Inhibitors of hepatitis c virus protease
06/26/2003WO2003051902A1 Neurotransmission-associated proteins
06/26/2003WO2003051872A1 Ethylene diamine derivatives and their use as orexin-receptor antagonists
06/26/2003WO2003051834A2 Immunocellular receptors related to neurological disorders
06/26/2003WO2003051832A2 Histamine h2 receptor and uses
06/26/2003WO2003051826A1 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
06/26/2003WO2003051418A1 Method and kit providing bioadhesive binding or coating with polyphenolic mussel proteins
06/26/2003WO2003051396A1 Treating vascular disease by inhibiting myeloid differentiation factor 88
06/26/2003WO2003051393A2 Enzymatic cleavable reagents for specific delivery to disease sites
06/26/2003WO2003051387A1 Remedies and/or preventives for conformational diseases
06/26/2003WO2003051377A1 Method for preparing fetuin and polypeptide to induce apoptosis
06/26/2003WO2003051310A2 Methods of inhibiting fertility
06/26/2003WO2003051305A2 Innate immune system-directed vaccines
06/26/2003WO2003051285A2 Therapeutic anti-hiv (iv9) compounds
06/26/2003WO2003035678A3 Sperm factor sequences
06/26/2003WO2003033651A3 Compositions and methods for promoting nematode resistance in plants
06/26/2003WO2003029408A3 Esr2 - a plant gene that can promote plant regeneration and transformation
06/26/2003WO2003027235A8 Afap sequences, polypeptides, antibodies and methods
06/26/2003WO2003026396A3 Transgenic mice containing socs-5 cytokine signalling suppressor gene disruptions
06/26/2003WO2003025125A3 Selective substrates for matrix metalloproteinases
1 ... 1579 1580 1581 1582 1583 1584 1585 1586 1587 1588 1589 1590 1591 1592 1593 1594 1595 1596 1597 1598 1599 ... 2916